ABOUT SYNGENE INTERNATIONAL
Syngene International Ltd. is a publicly listed, global CRDMO headquartered in Bengaluru, India, delivering integrated discovery, development, and manufacturing services to pharmaceutical and biotech innovators. With 6,500+ employees including ~5,000 scientists and cGMP manufacturing facilities across the U.S. and India, Syngene supports 400+ active clients globally through longterm, strategic partnerships.
End-To-End CRDMO Capabilities
Syngene provides end-to-end CRDMO services across small molecules, biologics, and advanced modalities. Its capabilities span discovery through commercial manufacturing, supported by dedicated R&D centers including its flagship Bristol Myers Squibb (BMS) dedicated center. The company has built strong platforms in TIDES (peptides and oligonucleotides) and XDCs, alongside a robust small molecule and biologics backbone. Manufacturing scale includes ~50 kL biologics capacity and ~135 kL small molecule capacity, complemented by commercial fill/finish capabilities up to ~1 million via ls/da y. Integrated platforms and automation enable seamless transition from discovery to development and commercial supply.
Quality, Scale, and Sustainability
Syngene operates globally accredited, cGMP-compliant facilities with approvals from US FDA, EMA and other regulators, supporting programs for regulated markets. The company has enabled innovation through 400+ pa tents with partners and continues to scale its global delivery model. Its ESG performance is a key differentiator, with >80% renewable energy usage, zero waste to landfill, and science-based emissions reduction targets. Backed by strong governance, global partnerships, and a growing international footprint, Syngene is a trusted partner in advancing therapies from lab to market.
RESEARCH & PERSPECTIVES
-
![anticancer drug, ADC-GettyImages-2148345960]( "ADCs As Biological Missiles For Targeted Therapies")
Antibody-drug conjugates are reshaping cancer treatment. Learn how monoclonal antibody targeting, linker design, and next-gen payloads are defining the future of precision oncology.
-
![digital exchange, money transfer-GettyImages-2148127398]( "Tech Transfer In CDMOs: Avoiding The Scale-Up Trap")
Tech transfer at a CDMO is a stress test, not a handover. Learn why lab-ready processes fail at scale and what chemical process development must address before manufacturing starts.
-
![GettyImages-1443975905 lab, analytics, technology]( "Batch Manufacturing Vs Continuous Manufacturing With Process Analytical Technology")
Batch or continuous manufacturing? The answer depends heavily on how you use process analytical technology. Understand the tradeoffs before your next program decision.
-
![Molecular biology, mRNA strands, genetics-GettyImages-2198118160]( "Self-Amplifying RNA: The Next Chapter In mRNA Therapeutics")
Self-amplifying RNA builds on mRNA technology by enabling intracellular replication, delivering stronger and longer-lasting responses at lower doses while improving scalability, cost-efficiency, and global accessibility.
-
![GettyImages-1207997703-dog-animal-vet-veterinarian]( "How Integrated Molecule Innovation Is Transforming Vet Therapeutics")
Cell line development underpins modern animal health innovation, enabling production of targeted biologics and supporting integrated approaches that improve therapeutic precision, scalability, and treatment outcomes.
VIDEOS & WEBINARS
CONTACT INFORMATION
Syngene International Ltd.
Biocon SEZ, Biocon Park, Plot.No.2 & 3, Bommasandra Indst Area IV Phase, Jigani Link Road
Bangalore, Karnataka, 560100
INDIA
Contact: Ishwarya S. Associate Director: Integrated Marketing, Ishwarya.S1@syngeneintl.com +91 8105521687
U.S. FACILITIES
Syngene International Ltd.
5901 E Lombard St.
Baltimore, MD 21224
BROCHURES
SUCCESS STORIES
-
![Pipette With Cell Culture Plate-GettyImages-520238063]( "Develop Clones In Just 9 Weeks From Transfection With Up To 4X Titer")
Transposon-based cell line development cuts timelines by 10 weeks and hits titers of 4.8 g/L in 17 days. See how SynWeave delivers measurable biologics manufacturing gains.
-
![GettyImages-824641956 monoclonal antibody]( "3X Bispecific Antibody Output, 98.5% Purity In 7 Months")
Producing bispecific antibodies at scale is notoriously difficult. See how Syngene achieved a 3X yield increase and 98.5% purity for Hinge Bio's GEM-DIMER™ platform in just seven months.
-
![Bioreactor for cell culture-GettyImages-517653054]( "Direct Scale Up From Clone To 2K GMP Batches")
N-1 perfusion technology increased antibody titers 1.5–4.5x over conventional fed-batch methods. See how high seed density and media blending cut costs and maximize suite utilization.
-
![GettyImages-1441343945-virus-viral-infection]( "Fast-Tracking NDA Approval For A Novel Compound To Treat Infections")
Strategic tech transfer and scalable manufacturing enabled rapid NDA approval, delivering registration batches and accelerating commercialization of a novel therapy for drug-resistant infections.
-
![GettyImages-2230550003 antibody receptor]( "Get Up To 4X Titer With N-1 Perfusion")
N-1 perfusion improves antibody production by increasing cell density, optimizing media and conditions, boosting yields up to 4.5× while maintaining quality and reducing manufacturing time and costs.
